Add BrightSurf on Google Email

Real-world studies confirm effectiveness of bulevirtide to treat chronic hepatitis D

Three real-world studies published in the Journal of Hepatology and JHEP Reports demonstrate that bulevirtide is well-tolerated and safe for treating chronic hepatitis delta. Long-term suppressive therapy with BLV monotherapy has the potential to reduce viral replication and improve liver function in difficult-to-treat patients.

SourceElsevier·JournalJournal of Hepatology·TypeExperimental study·DateMar 20, 2023

Scientists identify the mechanisms leading to resistance to lung cancer treatment with Sotorasib, the first KRAS inhibitor

Researchers studied how tumors adapt to Sotorasib and found that gene amplification and transcriptional programs lead to resistance. This knowledge can help develop targeted treatments for patients with KRAS mutations, potentially increasing survival rates.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalJournal of Clinical Investigation·TypeExperimental study·DateMar 17, 2023

New malaria study is good news for pregnant women

A new study published in The Lancet found that an existing drug, sulfadoxine-pyrimethamine, protects pregnant women from sexually transmitted and reproductive tract infections. Researchers tested this drug alongside a promising new treatment, dihydroartemisinin-piperaquine, which showed unique ability to prevent malaria.

SourceUniversity of Copenhagen - The Faculty of Health and Medical Sciences·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateMar 14, 2023

CHEST releases clinical practice guideline on respiratory management of patients with neuromuscular weakness

The American College of Chest Physicians released a clinical practice guideline on respiratory management for patients with neuromuscular weakness, providing evidence-based recommendations for mouthpiece ventilation and airway clearance therapies. The guideline aims to improve care for this vulnerable population.

SourceAmerican College of Chest Physicians·Journalthe journal CHEST·DateMar 14, 2023

Pusan National University develops novel biosensor to detect DNA damage in real time

Researchers at Pusan National University have developed a novel FRET-based biosensor to detect double-strand breaks in DNA, providing real-time information on γH2AX. The sensor's sensitivity is higher than conventional immunostaining techniques, making it useful for identifying DNA damage factors and elucidating repair mechanisms.

SourcePusan National University·JournalBiomaterials Research·TypeExperimental study·DateMar 13, 2023

A novel mechanism may be effective in patients with severe hypertriglyceridemia and prior episodes of acute pancreatitis

A phase 2 study found that ANGPTL3 inhibitor therapy reduced triglycerides by up to 70% in patients with severe hypertriglyceridemia who had previously experienced acute pancreatitis. The treatment, evicanumab-dgnb, also showed potential for cardiovascular prevention by reducing apolipoprotein B levels.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateMar 9, 2023

Exercise could help with common sexual complaint

A new study by Anglia Ruskin University found that physical activity and pelvic floor exercises can effectively increase latency time in men with premature ejaculation. The research suggests exercise as a promising non-pharmacological treatment option, potentially reducing the reliance on drugs with side effects.

SourceAnglia Ruskin University·JournalTrends in Urology & Men s Health·TypeLiterature review·DateMar 7, 2023

Transcatheter mitral valve repair in heart failure patients significantly reduces hospitalizations and improves survival

A new study shows that transcatheter mitral valve repair significantly reduces hospitalizations by almost 50 percent and death by nearly 30 percent in heart failure patients with severe mitral regurgitation. The procedure, using Abbott's MitraClip system, improves symptoms, reduces hospitalizations, and leads to longer survival.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateMar 5, 2023

Study: Seizures can be predicted more than 30 minutes before onset in patients with temporal lobe epilepsy

A study published in NEJM Evidence found that seizures can be predicted at least 35 minutes before onset in patients with temporal lobe epilepsy. This breakthrough discovery has significant implications for developing more effective therapies for this common seizure disorder, which affects over 50 million people globally.

Neoadjuvant pembrolizumab administered before surgery improves outcomes of melanoma patients

A phase 2 clinical trial shows that treating resectable stage 3 and 4 melanoma patients with pembrolizumab both before and after surgery greatly improves outcomes compared to pembrolizumab given only after surgery. This approach resulted in significantly longer event-free survival rates.

SourceH. Lee Moffitt Cancer Center & Research Institute·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateMar 1, 2023

Obesity makes it harder to diagnose and treat heart disease

A new review paper from Mayo Clinic outlines how obesity impacts common tests used to diagnose heart disease, such as ECG, CT scan, MRI, and echocardiogram. The study highlights the need for alternative approaches to prevent weight gain in patients with heart disease.

SourceMayo Clinic·JournalJournal of the American College of Cardiology·DateFeb 28, 2023

Nanosatellite shows the way to RNA medicine of the future

Scientists at Aarhus University and Berkeley Laboratory developed a method called RNA origami to design artificial RNA nanostructures. The technique allowed for the discovery of rules and mechanisms for RNA folding that will make it possible to build more ideal RNA particles for use in RNA-based medicine.

SourceAarhus University·JournalNature Nanotechnology·TypeExperimental study·DateFeb 27, 2023

More than 80% of American adults with type 2 diabetes meet treatment criteria for GLP-1 RAs or SGLT2is but most are not getting them

A study found that over 80% of American adults with type 2 diabetes meet the criteria to use GLP-1 RAs or SGLT2is, but only a small percentage are using them. The medications have a substantially higher cost than current first-line treatments, making it difficult for patients to access them.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeData/statistical analysis·DateFeb 27, 2023

When is remdesivir effective for COVID-19?

A new analysis of COVID-19 patient data reveals that remdesivir significantly lowers mortality in unvaccinated patients with conventional oxygen support. The study found no evidence of varying treatment effects based on age, comorbidities, or inflammation levels.

SourceUniversity of Basel·JournalThe Lancet Respiratory Medicine·TypeMeta-analysis·DateFeb 21, 2023

Journal of Pharmaceutical Analysis studies explore key traditional and modern therapeutics

Studies elucidate key aspects of traditional Chinese compounds and modern cancer therapeutics, highlighting the efficacy of R. serra in treating colitis and identifying active components of Gan Cao in treating pneumonia. A new radiolabeled antibody-based probe for detecting PD-L1 expression in cancers also provides a novel approach to ...

SourceCactus Communications·JournalJournal of Pharmaceutical Analysis·TypeExperimental study·DateFeb 14, 2023

Mission to beat rare cancers

Researchers at Helmholtz-Zentrum Dresden-Rossendorf developed a new strategy to increase target molecules for radionuclide therapy in pheochromocytoma tumors, delaying tumor growth. The combination of valproic acid and decitabine prior to therapy doubled the radiation dose absorbed by the tumor.

SourceHelmholtz-Zentrum Dresden-Rossendorf·JournalTheranostics·TypeExperimental study·DateFeb 9, 2023

What is clinically meaningful to slow Alzheimer’s progression?

The work group reframed what is clinically meaningful to slow Alzheimer's disease progression, including the need for combination therapies and realistic expectations of benefits and risks. Slowing brain deterioration by four to six months in early stages may preserve function, leading to meaningful outcomes for patients and families.

SourceMayo Clinic·JournalAlzheimer s & Dementia·DateFeb 7, 2023

Use of methotrexate is associated with an increased risk of skin cancer

A study by University of Gothenburg researchers found a significant association between methotrexate use and an increased risk of basal cell carcinoma, squamous cell carcinoma, and cutaneous malignant melanoma. The study suggests that higher doses of methotrexate may increase the risk of SCC and BCC, while no dose-response relationship...

SourceUniversity of Gothenburg·JournalBritish Journal of Cancer·TypeData/statistical analysis·DateFeb 7, 2023

Genomic methods aid study of Seattle 2017-2022 Shigella outbreak

A genomic study of the Seattle 2017-2022 Shigella outbreak revealed its origin as international travelers from areas where Shigella was common. The study also found that multi-drug resistant Shigella has become a growing global health concern, primarily affecting men who have sex with men and those experiencing homelessness.

SourceUniversity of Washington School of Medicine/UW Medicine·JournalThe Lancet Infectious Diseases·TypeObservational study·DateJan 31, 2023

Novel cancer therapy extends lives of terminally ill dogs

A novel form of chemoimmunotherapy has been proven to be a promising treatment for canine cancer, extending the lives of terminally ill dogs. The therapy uses modified Mesenchymal Stem Cells carrying a potent 'kill-switch' that induces anti-cancer immunity and improves quality of life.

SourceNational University of Singapore, Yong Loo Lin School of Medicine·JournalStem Cell Research & Therapy·TypeRandomized controlled/clinical trial·DateJan 30, 2023

LJI scientists uncover the structure and function of Inmazeb, the first FDA-approved drug for Ebola virus infection

Researchers at La Jolla Institute for Immunology have discovered the detailed mechanism of action of Inmazeb, a three-antibody cocktail designed to combat Ebola virus infection. The study reveals new information about how the drug interacts with the virus and its potential effectiveness against additional species of Ebolavirus.

SourceLa Jolla Institute for Immunology·JournalCell Host & Microbe·TypeExperimental study·DateJan 30, 2023

Advanced electronic skin for multiplex healthcare monitoring

Researchers from TIBI have developed an advanced electronic skin patch that provides simultaneous, continuous monitoring of multiple bodily parameters. The new E-skin patch offers enhanced flexibility, thermal cooling abilities, and fluid absorption over conventional substrates while demonstrating excellent biocompatibility and biodegr...

SourceTerasaki Institute for Biomedical Innovation·JournalAdvanced Materials·TypeExperimental study·DateJan 30, 2023

Primary care plays a role in helping patients with long COVID symptoms by providing holistic, trustworthy care

Researchers found that patients used various therapeutic strategies to alleviate symptoms, including mind-body medicine, nutritional supplements, exercise, and olfactory training. Many patients need more understanding, recognition, and specific post-COVID health care services, as well as empathy from their doctors.

SourceAmerican Academy of Family Physicians·JournalThe Annals of Family Medicine·DateJan 23, 2023

New hope for treatment of rare metabolic disease

A controlled clinical trial has shown that the new drug leriglitazone can prevent neurodegeneration and brain inflammation in patients with X-linked adrenoleukodystrophy. The study found improvements in neurological conditions such as balance disorders, which had a positive impact on quality of life.

SourceUniversität Leipzig·JournalThe Lancet Neurology·TypeRandomized controlled/clinical trial·DateJan 20, 2023

New precision therapy for bile duct cancer extends patients’ lives

A new personalized treatment for bile duct cancer has shown remarkable results, with patients surviving for up to two years when treated with the drug futibatinib. The Phase II clinical trial found that the drug was more effective at reducing tumor size and producing modest side effects compared to chemotherapy.

SourceUniversity College London·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateJan 18, 2023

Pusan National University researchers identify therapeutic targets to overcome radioresistance of brain cancer cells

A team of researchers from Korea and USA identified the importance of lipid homeostasis in overcoming brain cancer radioresistance. They found that regulating diacylglycerol kinase B and diacylglycerol acyltransferase 1 could potentially sensitize brain cancer cells to radiotherapy, offering a new treatment strategy.

SourcePusan National University·JournalCell Reports Medicine·TypeExperimental study·DateJan 18, 2023